UCN 01

Drug Profile

UCN 01

Alternative Names: 7-Hydroxystaurosporine; KRX-0601; KW-2401; NSC-638850; UCN-01; UCN-02

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Kyowa Hakko
  • Class Antineoplastics
  • Mechanism of Action 3 phosphoinositide dependent protein kinase 1 inhibitors; Checkpoint kinase 1 inhibitors; Phosphotransferase inhibitors; Protein kinase C inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Cancer; Lymphoma; Malignant melanoma; Myelodysplastic syndromes; Ovarian cancer; Pancreatic cancer; Small cell lung cancer; Solid tumours

Most Recent Events

  • 04 Apr 2008 Discontinued - Phase-I for Acute myeloid leukaemia in USA (IV-infusion)
  • 04 Apr 2008 Discontinued - Phase-I for Myelodysplastic syndromes in USA (IV-infusion)
  • 04 Apr 2008 Discontinued - Phase-I for Pancreatic cancer in USA (Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top